Pravastatin to Prevent Preeclampsia (NCT03944512) | Clinical Trial Compass
TerminatedPhase 3
Pravastatin to Prevent Preeclampsia
Stopped: participants are no longer being examined or receiving intervention
United States102 participantsStarted 2019-07-17
Plain-language summary
This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of a composite outcome of preeclampsia, fetal loss and maternal death. Women with a prior history of preeclampsia with preterm delivery less than 34 weeks will be randomized to pravastatin or placebo daily until delivery. Women will have monthly study visits during pregnancy, a follow-up visit at 6 weeks postpartum and children will have follow-up visits at 2 and 5 years of age.
Who can participate
Age range16 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. 16 years or older at time of consent with ability to give informed consent
ā. Single or twin gestation with cardiac activity in one or both fetuses. Higher order multifetal gestations reduced to twins, either spontaneously or therapeutically, are not eligible unless the reduction occurred by 13 weeks 6 days project gestational age.
ā. Gestational age at randomization between 12 weeks 0 days and 16 weeks 6 days based on clinical information and evaluation of the earliest ultrasound.
ā. Documented history (by chart or delivery/operative note review) of prior preeclampsia with delivery less than or equal to 34 weeks 0 days gestation in any previous pregnancy. If in the index pregnancy, the woman was induced by 34 weeks 0 days gestation and delivered within 48 hours in the same hospitalization, that woman would be eligible.
ā. Normal serum transaminase (AST/ALT) concentrations documented in the last 6 months.
Exclusion criteria
ā. Monoamniotic gestation because of the risk of fetal demise
ā. Known chromosomal, genetic or major malformations
What they're measuring
1
Proportion of Participants With Composite of Preeclampsia, Fetal Loss and Maternal Death
Timeframe: 48 hours postpartum
Trial details
NCT IDNCT03944512
SponsorThe George Washington University Biostatistics Center
. Fetal demise or planned termination of pregnancy. Selective reduction by 13 weeks 6 days gestation, from triplets to twins or twins to singleton is not an exclusion.
ā. Contraindications for statin therapy:
ā. Hypersensitivity to pravastatin or any component of the product
ā. Active liver disease: acute hepatitis or chronic active hepatitis
ā. Statin use in current pregnancy
ā. Patients with any of the following medical conditions: